Acorda Therapeutics (ACOR) Set to Announce Quarterly Earnings on Thursday

Acorda Therapeutics (NASDAQ:ACOR) will announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.07) per share for the quarter.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings data on Thursday, February 14th. The biopharmaceutical company reported $0.45 EPS for the quarter, beating the Zacks’ consensus estimate of ($1.19) by $1.64. Acorda Therapeutics had a net margin of 7.14% and a return on equity of 12.98%. The company had revenue of $69.20 million during the quarter, compared to the consensus estimate of $48.12 million. During the same quarter in the prior year, the company posted $0.61 EPS. The company’s quarterly revenue was down 63.3% compared to the same quarter last year. On average, analysts expect Acorda Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

NASDAQ ACOR opened at $11.17 on Thursday. Acorda Therapeutics has a 12 month low of $10.55 and a 12 month high of $36.35. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.77 and a quick ratio of 3.56. The stock has a market cap of $539.68 million, a PE ratio of 6.14 and a beta of 1.47.

In other news, major shareholder Scopia Capital Management Lp sold 11,001 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $16.02, for a total transaction of $176,236.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 18,762 shares of company stock valued at $298,336 in the last quarter. Company insiders own 7.80% of the company’s stock.

A number of research analysts have recently commented on ACOR shares. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Wednesday, December 26th. Cantor Fitzgerald set a $32.00 price objective on shares of Acorda Therapeutics and gave the company a “hold” rating in a research note on Wednesday, January 2nd. Raymond James reaffirmed a “sell” rating on shares of Acorda Therapeutics in a research note on Wednesday, December 26th. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price objective on shares of Acorda Therapeutics in a research note on Friday, January 4th. Finally, BidaskClub downgraded shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. Five equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $22.56.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Further Reading: Trading based on a resistance level

Earnings History for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with's FREE daily email newsletter.